Centessa Pharmaceuticals
Preço: 39.72Empresa e modelo de negócios
Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. Its core products include a pipeline of drug candidates targeting various diseases, primarily in oncology and rare diseases. The company operates through multiple business segments, emphasizing research and development to advance its therapeutic offerings. Major revenue sources are expected to stem from future product launches and collaborations with other pharmaceutical entities.
Perfil de investimento
The investment profile of Centessa Pharmaceuticals is more aligned with growth investors, given its focus on developing new therapies and the potential for future revenue generation. However, the high risk associated with its clinical-stage status may deter conservative investors. The stock may appeal to those with a longer investment horizon, as the company seeks to establish its market presence.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- -1.78 Risco
- Surpresa de EPS
- -36.8% pior que o esperado
- Volatilidade 20d
- 0.2% estável
Acompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-06-09 02:36 | Manter | Vender | Weak fundamentals and high risk limit upside potential. |
| 2026-06-01 02:34 | Vender | Manter | Weak fundamentals and high volatility signal caution. |
| 2026-05-16 02:53 | Manter | Vender | Weak fundamentals and high volatility raise concerns. |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-04-20 09:12 | Wells Fargo | Rating rebaixado | — → 42 | 39.66 |
| 2026-02-23 21:07 | Wolfe Research | Atualizar | — → 40 | 25.49 |
| 2026-01-29 14:25 | Truist Financial | Preço-alvo elevado | 33 → 38 | 24.73 |
Nada ainda